Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present SteadyMed Ltd. (NASDAQ: STDY).

Full DD Report for STDY

You must become a subscriber to view this report.


Recent News from (NASDAQ: STDY)

SteadyMed misses by $0.18
SteadyMed (NASDAQ: STDY ): Q1 EPS of -$0.39 misses by $0.18 . More news on: SteadyMed, Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: May, 15 2018 08:03
SteadyMed Provides Corporate Update and Reports First Quarter 2018 Financial Results
SAN RAMON, Calif., May 15, 2018 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parenteral delivery needs, today provided a corporate update and anno...
Source: GlobeNewswire
Date: May, 15 2018 08:00
The Law Offices of Vincent Wong Notifies Investors of an Investigation into SteadyMed Ltd. in Connection with the Sale of the Company to United Therapeutics Corporation - STDY
The Law Offices of Vincent Wong are investigating the Board of Directors of SteadyMed Ltd. (“SteadyMed” or the “Company”) (NASDAQGM: STDY) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Unite...
Source: Business Wire
Date: May, 07 2018 19:19
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces an Investigation of SteadyMed Ltd.- STDY
BALA CYNWYD, PA / ACCESSWIRE / May 3, 2018 / Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of SteadyMed Ltd. ("SteadyMed" or "the Company") (NASDAQ: STDY News) for possible breaches of fiduciary duty and other violat...
Source: ACCESSWIRE IA
Date: May, 03 2018 15:15
INVESTOR ALERT: Brower Piven Commences an Investigation into the Proposed Sale of SteadyMed Ltd. and Encourages Shareholders to Contact the Firm for Additional Information
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of SteadyMed Ltd. (Nasdaq: STDY) (“SteadyMed” or the “...
Source: Business Wire
Date: May, 03 2018 05:03
WeissLaw LLP Investigates SteadyMed Ltd.
NEW YORK , May 2, 2018 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of SteadyMed Ltd. ("STDY" or the "Company") (NASDAQ: STDY) in connection with the proposed acquisition of the Company by United Th...
Source: PR Newswire
Date: May, 02 2018 18:29
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Regarding Whether the Sale of SteadyMed Ltd. to United Therapeutics Corporation is Fair to Shareholders
The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased SteadyMed Ltd. (“SteadyMed” or the “Company”) (NASDAQGM: STDY) stock  prior to April 30, 2018 . You are hereby notified  that Lev...
Source: Business Wire
Date: May, 02 2018 12:35
Blog Exposure - United Therapeutics Acquired SteadyMed for Approximately $216 Million
LONDON, UK / ACCESSWIRE / May 02, 2018 / Active-Investors.com has just released a free research report on United Therapeutics Corp. (NASDAQ: UTHR ). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?...
Source: ACCESSWIRE IA
Date: May, 02 2018 07:20
United Therapeutics Inks Deal To Acquire SteadyMed
United Therapeutics ( UTHR ) has inked a deal with SteadyMed ( STDY ) that will see the former acquire the latter in a deal worth $216 million. The deal will see United pay $4.46 per share of SteadyMed, and will juice up the deal with another $2.63 per share when Trevyent, a drug for the tre...
Source: SeekingAlpha
Date: May, 01 2018 09:20
Premarket analyst action - healthcare
Eloxx Pharmaceuticals (NASDAQ: ELOX ) initiated with Overweight rating at Piper Jaffray. Shares up  7%  premarket. More news on: Eloxx Pharmaceuticals, Inc., Spark Therapeutics, Impax Laboratories, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: May, 01 2018 08:22

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-174.754.654.754.65114,150
2018-08-164.704.704.754.6526,003
2018-08-154.72154.7254.754.7067,823
2018-08-144.704.7254.754.7014,669
2018-08-134.754.7754.804.7512,213

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-1713,79018,46974.6657Short
2018-08-167,05411,60160.8051Short
2018-08-1517,63925,34069.6093Short
2018-08-142,9303,71778.8270Short
2018-08-131002,8753.4783Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on STDY.


About SteadyMed Ltd. (NASDAQ: STDY)

Logo for SteadyMed Ltd. (NASDAQ: STDY)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $124,891,779 - 05/11/2018
  • Issue and Outstanding: 26,572,719 - 03/15/2018

 


Recent Filings from (NASDAQ: STDY)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 15 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 15 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: May, 11 2018
Filing by person(s) reporting owned shares of common stock in a public company >5%
Filing Type: SC 13DFiling Source: edgar
Filing Date: May, 07 2018
Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: May, 01 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 30 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 30 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 30 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 30 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 30 2018

 

 


Daily Technical Chart for (NASDAQ: STDY)

Daily Technical Chart for (NASDAQ: STDY)


Stay tuned for daily updates and more on (NASDAQ: STDY)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: STDY)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in STDY is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of STDY and does not buy, sell, or trade any shares of STDY. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/